Embecta Corp

Hagens Berman has announced a lead plaintiff deadline of August 17, 2026 for investors in Embecta Corp. who suffered substantial losses during the class period from November 25, 2025 to May 4, 2026. The pending class action alleges that Embecta and its management misled investors about the stability of its insulin pen needle business, which was actually experiencing competitive share loss and market volume softness. On May 5, 2026, the company reported a massive revenue decline, slashed its full-year 2026 adjusted EPS guidance by approximately 43% at the midpoint, and cut its quarterly dividend by 93% from $0.15 to $0.01 per share, causing the stock to drop 57.8% in a single day. The firm is investigating whether Embecta’s prior assurances were materially false and misleading.

Pomerantz LLP has filed a class action lawsuit against Embecta Corp. over potential securities fraud. Investors who purchased or acquired Embecta securities during the class period have until August 17, 2026, to seek appointment as lead plaintiff. The lawsuit follows Embecta's May 5, 2026, announcement of second-quarter fiscal 2026 results, which revealed a revenue decline of over 14%—far exceeding prior guidance of flat to a 2% decline—and lowered full-year guidance, partly due to weakness in pen needle sales. On that news, Embecta's stock price fell nearly 58%, harming investors.

Rosen Law Firm reminds purchasers of Embecta Corp. common stock between November 25, 2025 and May 4, 2026 of the August 17, 2026 lead plaintiff deadline in a securities class action. The lawsuit alleges that Embecta made false or misleading statements and concealed adverse facts about its fiscal results, including touting its pen needle business as "incredibly resolute" weeks before missing expectations and cutting 2026 guidance. Investors who purchased shares during the class period may be entitled to compensation through a contingency fee arrangement. To join the class action or seek lead plaintiff status, investors must contact the firm before the deadline.

A class action lawsuit has been filed against Embecta Corp. and certain senior executives for securities fraud related to statements about its insulin pen needle product category. The suit, pending in the U.S. District Court for the District of New Jersey, alleges that Embecta misled investors by touting the strength of its insulin pen portfolio while facing significant competition and overall market softness. On May 5, 2026, the company announced disappointing second-quarter results and a dividend cut from $0.15 to $0.01 per share, causing its stock to drop 57.8% from $9.25 to $3.90 per share. Investors have until August 17, 2026 to seek lead plaintiff appointment.

The Law Offices of Howard G. Smith has issued a deadline alert for investors seeking to lead securities fraud class actions against First Solar, Embecta, Black Rock Coffee Bar, and Erasca. The lead plaintiff deadline for Erasca is August 10, 2026, while deadlines for Embecta and Black Rock Coffee Bar fall on August 17, 2026, and the deadline for First Solar is August 24, 2026. The complaints allege that each company made materially false or misleading statements or failed to disclose adverse facts about their business, operations, and prospects during the respective class periods. Investors who suffered losses are encouraged to contact the law firm to discuss their legal rights.

Robbins LLP reminds investors that a class action lawsuit has been filed against Embecta Corp. on behalf of purchasers of its securities between November 25, 2025 and May 4, 2026. The complaint alleges the medical device company misled shareholders by providing overly optimistic revenue guidance and reaffirming strength in its pen needle segment. On May 5, 2026, Embecta reported it missed second-quarter guidance, slashed its full-year 2026 guidance by 46%, and cut its dividend by 93%, causing the stock to drop over 57% to $3.90 per share. Shareholders seeking to serve as lead plaintiff must file with the court by August 17, 2026.

The Law Offices of Howard G. Smith reminds investors that securities fraud class action lawsuits have been filed against Embecta Corp., First Solar, Inc., ZoomInfo Technologies Inc., and Peabody Energy Corporation, with lead plaintiff deadlines in August 2026. The Embecta Corp. class action covers a class period from November 25, 2025 to May 4, 2026, with a lead plaintiff deadline of August 17, 2026, alleging the company made misleading statements about its guidance and failed to disclose segment weakness in the U.S. pen needle market. First Solar, Inc. faces a class period from February 26, 2025 to February 24, 2026, and a deadline of August 24, 2026, over claims it overstated its ability to manage U.S. tariff policy impacts and understated negative effects on fiscal 2026 performance. ZoomInfo Technologies Inc. has a class period from November 3, 2025 to May 11, 2026, and a deadline of August 24, 2026, with allegations that it failed to disclose slowing demand and weakening upsells that made its 2026 revenue guidance unattainable. Peabody Energy Corporation's class period runs from October 14, 2024 to May 4, 2026, with a deadline of August 24, 2026, and the complaint alleges the company made overly optimistic statements about its Centurion mine ramp-up and inflated guidance. Investors who suffered losses can contact the law firm to discuss their legal rights.

Bragar Eagel & Squire, P.C. has filed a class action lawsuit against Embecta Corp. in the United States District Court for the District of New Jersey. The suit represents investors who purchased or acquired Embecta common stock between November 25, 2025 and May 4, 2026. The complaint alleges that the company made materially false and misleading statements about its fiscal results and guidance, particularly regarding its pen needle business. On May 5, 2026, Embecta reported second-quarter earnings below expectations and cut its full-year 2026 guidance, citing a loss in its pen needle product category and market volume softness, causing shares to drop approximately 58% from $9.25 to $3.90. Investors have until August 17, 2026 to seek lead plaintiff appointment.

Hagens Berman is investigating Embecta Corp. for alleged violations of federal securities laws following a pending class action lawsuit. The lawsuit, filed in the U.S. District Court for the District of New Jersey, claims Embecta misrepresented the stability of its insulin pen needle business during the class period from November 25, 2025 to May 4, 2026. On May 5, 2026, Embecta reported a massive revenue decline and slashed its full-year 2026 adjusted EPS guidance by approximately 43% at the midpoint, while also cutting its quarterly dividend by 93% from $0.15 to $0.01 per share. The stock price fell 57.8% in a single trading day following the announcement. The firm is encouraging investors who suffered substantial losses to contact them before the August 17, 2026 lead plaintiff deadline.

The Gross Law Firm has issued a shareholder alert for Embecta Corp., announcing that investors who purchased EMBC shares between November 25, 2025 and May 4, 2026 may seek lead plaintiff appointment in a securities class action. The lawsuit alleges that Embecta made materially false and misleading statements about its fiscal results, touting its pen needle business as "incredibly resolute" just weeks before missing expectations and cutting fiscal 2026 guidance. On May 5, 2026, the company reported second-quarter results showing a revenue decline of over 14%, far worse than its prior guidance of flat to a 2% decline, and lowered its full-year outlook, citing weakness in U.S. pen needle sales. Following the disclosure, Embecta's stock fell from $9.25 per share to $3.90 per share, a single-day drop of over 57.8%. The deadline to apply for lead plaintiff is August 17, 2026.

Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Embecta Corp. and certain officers, alleging violations of federal securities laws. The suit covers investors who purchased Embecta securities between November 25, 2025 and May 4, 2026. The complaint claims defendants made false and misleading statements about the company's business, including touting its pen needle business as "incredibly resolute" shortly before missing expectations and cutting fiscal 2026 guidance. On May 5, 2026, Embecta reported second quarter fiscal 2026 results showing revenue declined over 14%, far worse than the prior guidance of flat to a 2% decline, and lowered its full-year outlook, partly due to weakness in pen needle sales. Investors have until August 17, 2026 to seek lead plaintiff appointment.

A class action lawsuit has been filed against Embecta Corp. and certain senior executives for securities fraud. The suit alleges the company misrepresented the strength of its insulin pen needle product category while facing significant competition and overall market softness. On May 5, 2026, Embecta announced disappointing Q2 2026 results below guidance due to share loss within its pen needle product category, mostly from a single customer, and reported a decline in insulin pen prescriptions. The news caused Embecta common stock to drop 57.8%, from $9.25 per share on May 4, 2026, to $3.90 per share on May 5, 2026. Investors have until August 17, 2026 to seek lead plaintiff appointment in the case pending in the U.S. District Court for the District of New Jersey.

Rosen Law Firm reminds purchasers of Embecta Corp. common stock between November 25, 2025 and May 4, 2026 of the August 17, 2026 lead plaintiff deadline in a securities class action. The lawsuit alleges that Embecta made false or misleading statements about its fiscal results and guidance, including touting its pen needle business as "incredibly resolute" shortly before missing expectations and cutting fiscal 2026 guidance. Investors who purchased shares during the class period may be entitled to compensation through a contingency fee arrangement without out-of-pocket costs. A class has not yet been certified, and investors may choose their own counsel or remain absent class members.

Embecta Corp. is facing a securities class action lawsuit on behalf of investors who purchased or acquired Embecta common stock between November 25, 2025 and May 4, 2026. The lawsuit alleges that the company misled investors by repeatedly assuring stability and resilience in its pen needle business, which historically comprised over 70% of total revenues, while concealing known competitive threats. On May 5, 2026, Embecta reported second-quarter adjusted earnings per share of $0.27, a roughly 61% sequential and year-over-year decline, and slashed its full-year adjusted EPS guidance to a range of $1.55 to $1.75, down about 43% at the midpoint, while also cutting its dividend by 93% to just $0.01. The complaint claims that Embecta knew or recklessly disregarded that weaknesses in the pen needle market would significantly disrupt its annual guidance and quarterly results. National shareholder rights firm Hagens Berman has opened an investigation into the matter, and the lead plaintiff deadline is August 17, 2026.

The Law Offices of Howard G. Smith reminds investors that securities fraud class actions have been filed against Embecta Corp., First Solar, Inc., ZoomInfo Technologies Inc., and Peabody Energy Corporation, with lead plaintiff deadlines ranging from August 17 to August 24, 2026. The Embecta suit, with a deadline of August 17, alleges the company misled investors about its guidance and U.S. pen needle market weakness. First Solar faces an August 24 deadline over claims it overstated its ability to manage tariff impacts and understated negative effects from production shifts. ZoomInfo, also with an August 24 deadline, is accused of hiding slowing demand and weakening upsells that made its 2026 revenue guidance unattainable. Peabody Energy, with the same August 24 deadline, allegedly misrepresented the ramp-up timeline and guidance for its Centurion mine. Investors who suffered losses can contact the firm to discuss their legal rights.

Bleichmar Fonti & Auld LLP announces that investors in Embecta Corp. have until August 17, 2026, to seek lead plaintiff appointment in a securities fraud class action filed after the company's stock dropped 57.8% on May 5, 2026. The lawsuit, pending in the U.S. District Court for the District of New Jersey under the caption Apitz-Grossman v. Embecta Corp., et al., alleges that Embecta misled investors about the strength of its insulin pen needle product category while facing significant competition and overall market softness. On May 5, 2026, Embecta reported disappointing second-quarter results below guidance, citing share loss within its pen needle category and a decline in insulin pen prescriptions, and slashed its quarterly dividend from $0.15 to $0.01 per share. The stock fell from $9.25 per share on May 4, 2026, to $3.90 per share on May 5, 2026. The firm represents investors on a contingency fee basis with no upfront costs.

Rosen Law Firm reminds purchasers of Embecta Corp. common stock between November 25, 2025 and May 4, 2026 of the August 17, 2026 lead plaintiff deadline in a securities class action. The lawsuit alleges that Embecta made false or misleading statements about its fiscal results and guidance, including touting its pen needle business as "incredibly resolute" shortly before missing expectations and cutting fiscal 2026 guidance. Investors who bought shares during the class period may be entitled to compensation through a contingency fee arrangement without out-of-pocket costs. A class has not yet been certified, and investors may choose their own counsel or remain absent class members.

Glancy Prongay Wolke & Rotter LLP reminds Embecta Corp. shareholders of the August 17, 2026 deadline to file a lead plaintiff motion in a securities fraud class action. The lawsuit covers investors who purchased Embecta common stock between November 25, 2025 and May 4, 2026. The complaint alleges the company made misleading statements and failed to disclose that its guidance was unattainable and that weakness in the U.S. pen needle market would disrupt revenue. On May 5, 2026, Embecta reported a revenue decline of over 14% and lowered its fiscal 2026 guidance, causing its stock to drop 57.8% to $3.90 per share.

Levi & Korsinsky alerts Embecta Corp. investors of a pending securities class action covering purchases between November 25, 2025 and May 4, 2026. The lawsuit alleges management concealed significant share loss concentrated at a single major customer and overall retail channel volume softness for insulin pens and pen needles, while describing the pen needle segment as incredibly resolute and reaffirming full-year guidance. On May 5, 2026, Embecta shares fell 57.8 percent, or $5.35, to $3.90 after the company disclosed massive U.S. revenue shortfalls. The complaint states that pen needle revenue was reduced by approximately $53 million, accounting for 70 percent of a total $75 million guidance cut, with competitive share loss at the single customer driving an estimated $25 million of that reduction. The court has set August 17, 2026 as the deadline to apply for lead plaintiff appointment.

Embecta Corp. is facing a securities class action lawsuit on behalf of investors who purchased or acquired Embecta common stock between November 25, 2025 and May 4, 2026. The lawsuit alleges that the company made misleading assurances about the stability and resilience of its pen needle business, which historically comprised over 70% of total revenues, while knowing or recklessly disregarding weaknesses in the pen needle market that were likely to significantly disrupt its annual guidance and second-quarter results. On May 5, 2026, Embecta reported second-quarter adjusted earnings per share of $0.27, a roughly 61% sequential and year-over-year decline, and slashed its full-year 2026 adjusted EPS guidance to $1.55 to $1.75, down about 43% at the midpoint, while also reducing its dividend by 93% to just $0.01. The stock price tumbled following the report, and shareholder rights firm Hagens Berman has opened an investigation into potential violations of federal securities laws. The lead plaintiff deadline is August 17, 2026.

A securities fraud class action lawsuit has been filed against Embecta Corp. and certain senior executives following a 57.8% stock drop on May 5, 2026. The complaint alleges that Embecta misled investors about the strength of its insulin pen needle product category, while in reality it faced significant competition and overall market softness. The stock decline occurred after the company announced disappointing second-quarter 2026 results that missed guidance due to share loss in its pen needle category, mostly from a single customer, and reduced its quarterly dividend from $0.15 to $0.01 per share. Investors have until August 17, 2026 to seek lead plaintiff appointment in the case pending in the U.S. District Court for the District of New Jersey.

Faruqi & Faruqi, LLP reminds investors of the August 17, 2026 deadline to seek lead plaintiff in a securities class action against Embecta Corp. The lawsuit alleges Embecta made false and misleading statements about its financial guidance, touting its pen needle business as "incredibly resolute" weeks before missing expectations and cutting fiscal 2026 guidance. On May 5, 2026, Embecta reported a revenue decline of over 14% for the second quarter, far exceeding its guided range of flat to a 2% decline, largely due to weakness in pen needle sales. The stock fell from $9.25 to $3.90 per share, a drop of over 57.8% in a single day. Investors who purchased Embecta securities between November 25, 2025 and May 4, 2026 may be eligible to participate.

Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Embecta Corp. and certain officers, alleging violations of federal securities laws. The suit covers investors who purchased or acquired Embecta securities between November 25, 2025 and May 4, 2026. The complaint claims the company made false and misleading statements about its business, including describing its pen needle business as incredibly resolute shortly before missing expectations and cutting fiscal 2026 guidance. On May 5, 2026, Embecta reported a revenue decline of over 14%, far worse than its guidance of flat to a 2% decline, and lowered its outlook due in part to weakness in pen needle sales. Investors have until August 17, 2026 to seek lead plaintiff appointment.

Robbins LLP reminds stockholders that a class action has been filed on behalf of investors who purchased Embecta Corp. securities between November 25, 2025 and May 4, 2026. The lawsuit alleges that Embecta misled investors by providing overly optimistic guidance for fiscal year 2026, particularly regarding its pen needle segment. On May 5, 2026, the company reported it missed second-quarter guidance, lowered full-year guidance by 46%, and cut its dividend by 93%, causing its stock price to drop over 57% to $3.90 per share. Shareholders who wish to serve as lead plaintiff must file papers by August 17, 2026.

The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of Embecta Corp., Black Rock Coffee Bar, Inc., and First Solar, Inc. For Embecta, the class period is November 25, 2025 to May 4, 2026, with a lead plaintiff deadline of August 17, 2026; the complaint alleges the company made misleading statements about its guidance and failed to disclose segment weakness in the U.S. pen needle market. For Black Rock Coffee Bar, the class period is September 12, 2025 to May 12, 2026, also with an August 17, 2026 deadline; the complaint alleges the company failed to disclose that new store openings were cannibalizing existing revenue and that its expansion strategy overstated avoidance of sales transfer. For First Solar, the class period is February 26, 2025 to February 24, 2026, with a lead plaintiff deadline of August 24, 2026; the complaint alleges the company overstated its ability to manage U.S. tariff policy impacts and understated the negative effects of production facility underutilization and relocation on fiscal 2026 performance.

Bragar Eagel & Squire, P.C. has filed a class action lawsuit against Embecta Corp. in the United States District Court for the District of New Jersey on behalf of investors who purchased Embecta common stock between November 25, 2025 and May 4, 2026. The complaint alleges that the company made materially false and misleading statements about its fiscal results and guidance, particularly regarding its pen needle business, which was described as "incredibly resolute" shortly before a disappointing earnings report. On May 5, 2026, Embecta reported second-quarter results below analyst expectations and cut its full-year 2026 guidance, citing a loss in the pen needle category and soft market volume, causing its share price to drop approximately 58% from $9.25 to $3.90. Investors have until August 17, 2026 to seek lead plaintiff appointment.

Robbins LLP has filed a class action lawsuit on behalf of investors who purchased Embecta Corp. securities between November 25, 2025 and May 4, 2026. The complaint alleges that Embecta misled investors by providing overly optimistic revenue guidance and reaffirming strength in its pen needle segment. On May 5, 2026, Embecta reported second quarter fiscal 2026 results showing a revenue decline of over 14%, far worse than its guidance of flat to a 2% decline, and lowered its full-year outlook, citing weakness in pen needle sales. Following the news, Embecta's stock price fell to $3.90 per share. Shareholders who wish to serve as lead plaintiff must contact Robbins LLP before the deadline.

Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities fraud class action has been filed against Embecta Corp. on behalf of those who purchased or acquired shares between November 25, 2025 and May 4, 2026. The complaint alleges that defendants made positive statements while concealing the true state of Embecta's fiscal results, particularly regarding its pen needle business. On May 5, 2026, Embecta reported second quarter fiscal 2026 results that missed guidance and lowered full-year guidance, revealing a revenue decline of over 14% compared to prior guidance of 0% to a 2% decline, partly due to weakness in pen needle sales. The stock price fell from $9.25 per share on May 4, 2026 to $3.90 per share on May 5, 2026, a single-day decline of over 57.8%. Investors who suffered losses have until August 17, 2026 to file a motion to serve as lead plaintiff.

Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Embecta Corp. and certain officers, alleging violations of federal securities laws. The suit covers investors who purchased or acquired Embecta securities between November 25, 2025 and May 4, 2026. The complaint claims defendants made false and misleading statements about the company's business, including touting its pen needle business as 'incredibly resolute' shortly before missing expectations and cutting fiscal 2026 guidance. On May 5, 2026, Embecta reported second-quarter fiscal 2026 results showing revenue declined over 14%, far worse than prior guidance of flat to a 2% decline, and lowered its full-year outlook, citing weakness in pen needle sales. Investors have until August 17, 2026 to seek lead plaintiff appointment.